Charles Joel Rosser

Dr. Rosser obtained a BS degree in Biology from Fairleigh Dickinson University and an MD from Rutgers University School of Medicine (Robert Wood Johnson Medical School). Subsequently he performed his residency at Wake Forest University School of Medicine and fellowship at UT MD Anderson Cancer Center. He has held professorships at the University of Florida, the University of Central Florida and the University of Hawaii. Currently, he is Professor at the Samuel Oschin Comprehensive Cancer Institute at Cedars-Sinai Medical Center. Dr. Rosser has been principal investigator in over 60 clinical trials and has garnered over $15 million in extramural funding from such entities as American Cancer Society, Department of Defense and National Cancer Institute.

In addition, he has authored over 200 peer reviewed research articles. His research interests include molecular diagnostics and experimental therapeutics. Dr. Rosser has played a critical role in the development of N-803 (ALT-803), an IL15 analogue used in combination with BCG to treated bladder cancer, which has granted Breakthrough and Fast Track designation by the FDA.